Endocrine Therapy of Breast Cancer IV

1. Front Matter

   Pages I-VII

   PDF

2. Introduction

   • A. Goldhirsch

   Pages 1-1

3. Role of Oestrogen and Progestin in Human Mammary Carcinogenesis

   • R. J. B. King

   Pages 3-8

4. Molecular Genetics of Steroid Hormone Receptors

   • E. Milgrom

   Pages 9-16

5. Prognostic Factors in Breast Cancer

   • Jan G. M. Klijn, John A. Foekens

   Pages 17-30

6. Prognostic Factors in Node-Negative Breast Cancer Patients

   • Ingegerd Balslev, Karin Zedeler, Susan M. Thorpe, Birgitte Bruun Rasmussen, Henning T. Mouridsen

   Pages 31-41

7. Long-Term Tamoxifen Therapy: An Appropriate Chemosuppressive Treatment for Breast Cancer

   • V. Craig Jordan

   Pages 43-47

8. Tamoxifen as an Agonist for Metastatic Breast Cancer

   • Anthony Howell, David J. Dodwell, Ian Laidlaw, Heather Anderson, Elizabeth Anderson

   Pages 49-58

9. A Review of the International Experience with the LHRH Agonist Zoladex in the Treatment of Advanced Breast Cancer in Pre- and Perimenopausal Women

   • R. A. V. Milsted, M. J. Matthews

   Pages 59-65

10. Adjuvant Systemic Therapy in Node-Negative Breast Cancer

    • Manfred Kaufmann

    Pages 67-76

11. Adjuvant Chemotherapy in Premenopausal Breast Cancer Patients is Effective by Means Other than Ovarian Function Suppression

    • A. Goldhirsch, R. D. Gelber, M. Castiglione

    Pages 77-86

12. Alternative Methods for Describing Treatment Benefit Including Quality-of-Life Considerations

    • R. D. Gelber, A. Goldhirsch

    Pages 87-97

The European School of Oncology came into existence to respond to a need for informa­ tion, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was. considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Univer­ sities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly. With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice. One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of oncology.

• Hormonrezeptoren
• Ovarsuppression
• breast cancer
• cancer
• carcinogenesis
• cell
• chemotherapy
• genetics
• hormone
• hormone receptors
• hormones
• molecular genetics
• oncology
• steroid
• systemic therapy

• Department of Medical Oncology, Ospedale Civico, Lugano, Switzerland

  A. Goldhirsch

Policies and ethics